Back to top
more

Inovio Pharmaceuticals (INO)

(Delayed Data from NSDQ)

$1.49 USD

1.49
1,279,561

+0.05 (3.47%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $1.41 -0.08 (-5.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (141 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why

by Zacks Equity Research

Inovio Pharma (INO) surges 134% in a month, mainly due to its plans to submit a regulatory application seeking approval of its lead candidate, INO-3107, in the second half of 2024 to treat RRP.

Zacks Equity Research

Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why

by Zacks Equity Research

Inovio Pharma (INO) rises 19% this month after the FDA issues positive feedback on data from a phase I/II study on a rare respiratory disease candidate, INO-3107, which can be used to file a BLA.

Zacks Equity Research

Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of 7.14% and 13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up

by Zacks Equity Research

INOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare respiratory tract disease, INO-3107, receives orphan drug designation from the European Commission.

Zacks Equity Research

All You Need to Know About Inovio (INO) Rating Upgrade to Buy

by Zacks Equity Research

Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of -14.29% and 42.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agenus (AGEN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -4.76% and 2.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 4.62% and 5%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

First Wave (FWBI) IND Filing Under FDA's Review, Stock Up

by Zacks Equity Research

First Wave's (FWBI) stock gains as FDA reviews its IND amendment for the planned phase II study of an enhanced enteric microgranule delivery formulation of adrulipase.

Zacks Equity Research

ETON Up as FDA Accepts NDA for Dehydrated Alcohol Injection

by Zacks Equity Research

Eton (ETON) gains as the its new drug application (NDA) for dehydrated alcohol injection for methanol poisoning is accepted for review by the FDA.

Zacks Equity Research

bluebird (BLUE) Updates on Progress With Zynteglo, 2023 Outlook

by Zacks Equity Research

bluebird bio, Inc. (BLUE) updates on the launch of gene therapy Zynteglo and provides cash burn guidance for 2023.

Zacks Equity Research

Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of 48.28% and 3,880%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -12.73% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Immunocore Holdings PLC Sponsored ADR (IMCR): Can Its 10.2% Jump Turn into More Strength?

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate

by Zacks Equity Research

Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.

Zacks Equity Research

Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of -53.33% and 264.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Inovio Pharmaceuticals (INO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of -28.57% and 56.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -1.59% and 24.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biogen Inc. (BIIB) Q1 Earnings Miss Estimates

by Zacks Equity Research

Biogen Inc. (BIIB) delivered earnings and revenue surprises of -17.91% and 1.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Repligen (RGEN) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 27.78% and 12.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inovio Pharmaceuticals (INO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of -51.52% and 301.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alkermes (ALKS) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 76.92% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums

by Zacks Equity Research

Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.